secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001935979-25-000067
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven reports Q2 net loss $198M, cash $408.2M; OCD trial fails, VYGLXIA PDUFA in Q4 2025
--------------------------------------------------------------------------------

- Net loss of $198.1M ($1.94 per share) vs $319.8M in Q2 2024; no revenue, clinical-stage biopharma.
- Cash, equivalents and marketable securities $408.2M as of June 30, 2025.
- Phase 3 OCD trial with troriluzole showed no efficacy signal; program terminated.
- VYGLXIA NDA for spinocerebellar ataxia under priority review, PDUFA in Q4 2025.
- Early clinical data: BHV-1300 IgG reductions up to 87%, BHV-1510 ADC showed tumor reduction in first 6/6 patients with cemiplimab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/0001935979-25-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/bhvn-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001935979-25-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer